دورية أكاديمية
أعرض في EDS

Evaluation of the safety and feasibility of electrochemotherapy with intravenous bleomycin as local treatment of bladder cancer in dogs.

التفاصيل البيبلوغرافية
العنوان: Evaluation of the safety and feasibility of electrochemotherapy with intravenous bleomycin as local treatment of bladder cancer in dogs.
المؤلفون: Rangel MMM; VetCancer Veterinary Oncology, São Paulo, São Paulo, Brazil., Linhares LCM; School of Agricultural and Veterinary Sciences, São Paulo State University (UNESP) 'Júlio de Mesquita Filho', Jaboticabal, São Paulo, Brazil. lais.menescal@unesp.br., de Oliveira KD; VCLab Pathology, São Paulo, São Paulo, Brazil., Suzuki DOH; Institute of Biomedical Engineering, Federal University of Santa Catarina (UFSC), Florianopolis, Santa Catarina, Brazil., Maglietti FH; Instituto Universitario de Ciencias de la Salud. Fundación Barceló-CONICET, Buenos Aires, Argentina., de Nardi AB; School of Agricultural and Veterinary Sciences, São Paulo State University (UNESP) 'Júlio de Mesquita Filho', Jaboticabal, São Paulo, Brazil.
المصدر: Scientific reports [Sci Rep] 2023 Nov 29; Vol. 13 (1), pp. 21078. Date of Electronic Publication: 2023 Nov 29.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Electrochemotherapy*/methods , Carcinoma, Transitional Cell*/drug therapy , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/veterinary , Urinary Bladder Neoplasms*/chemically induced , Skin Neoplasms*/drug therapy, Dogs ; Animals ; Humans ; Bleomycin ; Antibiotics, Antineoplastic ; Prospective Studies ; Feasibility Studies ; Treatment Outcome
مستخلص: Local treatment of canine urothelial carcinoma (UC) of the bladder is a challenge. More than 90% of the cases invade the muscular layer, more than 50% develop on bladder sites with a difficult surgical approach and often requiring radical surgical procedures. This study aims to evaluate the safety and feasibility of electrochemotherapy (ECT) with intravenous bleomycin (BLM) as a local therapy for bladder UC. This prospective study included 21 dogs with spontaneous bladder UC. Regional/distant metastases and neoplastic infiltration of the serosa was considered the main exclusion criteria. We had no deaths during ECT or in the immediate postoperative period, and no suture dehiscence. Most dogs (19/21) developed mild adverse effects, whereas two dogs developed ureteral stenosis. Complete response (CR) was achieved in 62% of the cases (13/21), while partial response (PR) was achieved in 24% (5/21). The median survival and disease-free survival times were 284 and 270 days, respectively. Overall survival was significantly better in the dogs who achieved a CR. In conclusion, ECT was well-tolerated in dogs with UC, demonstrating its safety and feasibility. These data pave the way for new studies aimed at evaluating the effectiveness of ECT in canine bladder UC as a translational model for human disease.
(© 2023. The Author(s).)
References: J Vet Intern Med. 2013 Sep-Oct;27(5):1136-42. (PMID: 24033421)
Vet Radiol Ultrasound. 2016 May;57(3):341-51. (PMID: 26841125)
Oncol Lett. 2015 Apr;9(4):1515-1519. (PMID: 25788992)
J Transl Med. 2017 Apr 26;15(1):82. (PMID: 28441954)
Biomedicines. 2021 Oct 14;9(10):. (PMID: 34680588)
Vet Sci. 2021 Mar 22;8(3):. (PMID: 33809822)
Vet Comp Oncol. 2021 Jun;19(2):311-352. (PMID: 33427378)
Cancer Res. 1993 Nov 15;53(22):5462-9. (PMID: 7693342)
Biochem Pharmacol. 1988 Dec 15;37(24):4727-33. (PMID: 2462423)
Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774)
J Vet Intern Med. 1992 May-Jun;6(3):145-53. (PMID: 1619591)
Int J Surg. 2015 Jun;18:230-6. (PMID: 25917204)
Eur J Surg Oncol. 2018 May;44(5):651-657. (PMID: 29402556)
Mol Cancer Ther. 2021 Nov;20(11):2177-2188. (PMID: 34433660)
Sci Rep. 2022 Jan 13;12(1):4. (PMID: 35027594)
Radiol Oncol. 2016 Feb 16;50(1):1-13. (PMID: 27069444)
J Vet Intern Med. 2011 Nov-Dec;25(6):1385-90. (PMID: 22092632)
Front Oncol. 2020 Jan 21;9:1493. (PMID: 32039002)
Can Vet J. 2015 Jan;56(1):73-80. (PMID: 25565719)
J Vet Intern Med. 2013 Jan-Feb;27(1):126-33. (PMID: 23205923)
Bladder Cancer. 2016 Apr 27;2(2):241-250. (PMID: 27376143)
J Am Vet Med Assoc. 2011 Apr 15;238(8):1004-10. (PMID: 21492043)
J Am Vet Med Assoc. 2013 Feb 15;242(4):499-506. (PMID: 23363282)
Urol Oncol. 2000 Mar-Apr;5(2):47-59. (PMID: 21227289)
Open Vet J. 2021 Oct-Dec;11(4):535-543. (PMID: 35070848)
Radiol Oncol. 2017 Nov 01;51(4):422-430. (PMID: 29333121)
J Small Anim Pract. 1996 Oct;37(10):480-5. (PMID: 8912242)
J Am Anim Hosp Assoc. 2019 Sep/Oct;55(5):243-248. (PMID: 31433219)
J Am Vet Med Assoc. 2018 May 1;252(9):1073-1083. (PMID: 29641337)
Med Sci (Basel). 2020 Mar 13;8(1):. (PMID: 32183076)
Tohoku J Exp Med. 1994 Mar;172(3):291-3. (PMID: 7521075)
Can Vet J. 2021 Feb;62(2):133-140. (PMID: 33542551)
Front Vet Sci. 2022 Jul 27;9:868989. (PMID: 35968026)
J Vet Intern Med. 2013 Sep-Oct;27(5):1113-20. (PMID: 23952553)
Vet Comp Oncol. 2017 Dec;15(4):1417-1427. (PMID: 28217972)
Vet J. 2015 Aug;205(2):217-25. (PMID: 25747698)
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7. (PMID: 16442208)
Vet Radiol Ultrasound. 2002 Mar-Apr;43(2):187-92. (PMID: 11954816)
Int J Radiat Oncol Biol Phys. 1988 May;14(5):939-46. (PMID: 3129384)
Vet Surg. 2014 Mar;43(3):294-300. (PMID: 24433358)
Cancer Immunol Res. 2019 Jul;7(7):1175-1187. (PMID: 31160277)
ILAR J. 2014;55(1):100-18. (PMID: 24936033)
Urol Res. 2000 Dec;28(6):391-7. (PMID: 11221918)
Vet Comp Oncol. 2005 Jun;3(2):73-80. (PMID: 19379215)
Vet Surg. 2017 Jan;46(1):111-119. (PMID: 27911468)
Bladder Cancer. 2018 Apr 26;4(2):149-159. (PMID: 29732386)
Open Vet J. 2021 Jan-Mar;11(1):100-106. (PMID: 33898290)
Eur Urol. 2013 Feb;63(2):234-41. (PMID: 22877502)
Vet Clin North Am Small Anim Pract. 2019 Sep;49(5):967-979. (PMID: 31176458)
World J Urol. 2019 Jan;37(1):51-60. (PMID: 30109483)
J Vet Intern Med. 2012 Jul-Aug;26(4):987-95. (PMID: 22624845)
J Am Anim Hosp Assoc. 2004 Mar-Apr;40(2):131-6. (PMID: 15007049)
Drug Deliv. 2002 Oct-Dec;9(4):249-52. (PMID: 12511203)
Oncotarget. 2017 May 9;8(34):57766-57781. (PMID: 28915710)
Oncol Lett. 2018 Aug;16(2):1641-1649. (PMID: 30008848)
Eur J Surg Oncol. 2020 May;46(5):847-854. (PMID: 31862134)
J Vet Intern Med. 1994 Jul-Aug;8(4):273-8. (PMID: 7983623)
Vet Res Forum. 2020 Summer;11(3):289-293. (PMID: 33133468)
Clin Cancer Res. 2003 Feb;9(2):906-11. (PMID: 12576466)
Cancer Chemother Pharmacol. 1996;39(1-2):67-70. (PMID: 8995501)
Res Vet Sci. 2011 Feb;90(1):156-9. (PMID: 20542305)
Vet Comp Oncol. 2018 Mar;16(1):E117-E122. (PMID: 28884928)
Hum Pathol. 2012 Dec;43(12):2097-108. (PMID: 22542126)
معلومات مُعتمدة: 88887.706252/2022-00 Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
المشرفين على المادة: 11056-06-7 (Bleomycin)
0 (Antibiotics, Antineoplastic)
تواريخ الأحداث: Date Created: 20231129 Date Completed: 20231201 Latest Revision: 20231221
رمز التحديث: 20231221
مُعرف محوري في PubMed: PMC10687251
DOI: 10.1038/s41598-023-45433-4
PMID: 38030630
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-023-45433-4